rVSV S GP/VP40
Alternative Names: BPSC-1001; Ebola vaccine - Merck & Co; Ebola virus vaccine - Lumos Pharma; ERVEBO; Public Health Agency of Canada's Ebola vaccine; rVSV delta G ZEBOV GP; rVSV-EBOV; rVSV-S-GP/VP40; rVSV-ZEBOV; rVSV-ZEBOV-GP; rVSVΔG-ZEBOV-GP; V-920; V920 Ebola Zaire Vaccine; VSV delta G ZEBOV; VSV delta-ZEBOV; VSV-EBOV; VSV-ZEBOV; VSVG-ZEBOVLatest Information Update: 18 Jul 2024
At a glance
- Originator Public Health Agency of Canada
- Developer Canadian Immunization Research Network; Dalhousie University; Merck & Co; National Institute of Allergy and Infectious Diseases
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Ebola virus infections
Most Recent Events
- 20 Dec 2023 National Institute of Allergy and Infectious Diseases completes a phase II trial in Ebola virus infections (In infants, In children, In adolescents, In adults, In the elderly, Prevention) in Guinea, Liberia, Sierra Leone, Mali (IM) (NCT02876328)
- 20 Oct 2023 Merck Sharp & Dohme in collaboration with Emory University plans a phase II trial for Ebola virus infections in USA (IM, Injection) (NCT06100913)
- 07 Sep 2023 Registered for Ebola virus infections (In adolescents, In children, In the elderly, In infants, Prevention, In adults) in Iceland, Liechtenstein, Norway, European Union (IM)